A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.

Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

Novo Nordisk’s CEO Lars Fruergaard Jørgensen faced tough congressional scrutiny over the high prices of its obesity ...

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

With 890 million people affected globally and 42% of American adults classified as obese, the allure of a "miracle" weight ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Pharmaceutical corporations Eli Lilly, Novo Nordisk, and Sanofi have been challenged by Doctors Without Borders to take ...

Neither company accepts insurance for their GLP-1 products, but the versions they sell are vastly cheaper than those sold by ...

With a reduction in borrowing costs and consequent availability of cheaper capital, drugmakers can ramp up their R&D spending ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...